ArticleHuman cell2025
Metformin promotes osteogenic differentiation of human periodontal ligament stem cells via KLF2-mediated activation of miR-181a-5p under lipopolysaccharide stimulation.
Article in Human cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dose-dependent effects of Metformin on proliferation and odontogenic differentiation of dental pulp stem cells.BMC oral health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Periodontal ligament stem cells (PDLSCs) constitute a promising source for successful periodontal regeneration. This study aims to explore roles of metformin, krüppel-like factor 2 (KLF2), and miR-181a-5p in mediating osteogenic differentiation of human PDLSCs (hPDLSCs) following lipopolysaccharide (LPS) stimulation. The osteogenic differentiation potential of hPDLSCs isolated from human premolar root samples were examined by alkaline phosphatase (ALP) staining, ALP activity assay, Alizarin red S staining, and Western blotting of osteogenic markers. Metformin pretreatment at dose of 100 μM significantly resulted in increased ALP activity, elevated protein expressions of osteogenic markers, and more generated mineralized matrix in hPDLSCs with LPS stimulation. KLF2 and miR-181a-5p were found to be increased by metformin pretreatment at dose of 100 μM in hPDLSCs with stimulation but not in hPDLSCs without LPS stimulation. The interaction between the KLF2 and the promoter of miR-181a-5p was noted by the dual-luciferase reporter assay. KLF2 knockdown or miR-181a-5p inhibition notably abrogated the improvements of osteogenic differentiation by metformin pretreatment in LPS-stimulated hPDLSCs. The findings of the study indicate metformin protects hPDLSCs against impaired osteogenic differentiation of hPDLSCs after LPS stimulation by KLF2-mediated activation of miR-181a-5p under inflammation conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.